Related Experiment Video
Updated: Jul 4, 2026

Assays for the Specific Growth Rate and Cell-binding Ability of Rotavirus
Published on: January 28, 2019
Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency
Michelle G Goveia1, Mark J DiNubile, Michael J Dallas
1From Merck & Co., Inc., West Point, PA, USA.
Insights
This study found that breastfeeding frequency did not negatively impact the effectiveness of the pentavalent rotavirus vaccine in preventing rotavirus gastroenteritis (RVGE). The vaccine demonstrated high efficacy across all breastfeeding groups.
Area of Science:
- Pediatrics
- Vaccinology
- Infectious Diseases
Background:
- Rotavirus gastroenteritis (RVGE) is a significant cause of infant morbidity worldwide.
- The pentavalent rotavirus vaccine is a key intervention for RVGE prevention.
- Breastfeeding is known to provide passive immunity, raising questions about its interaction with vaccine efficacy.
Purpose of the Study:
- To retrospectively assess the efficacy of a live, oral, pentavalent rotavirus vaccine.
- To determine if breastfeeding frequency influences vaccine efficacy against rotavirus gastroenteritis (RVGE).
Main Methods:
- A retrospective analysis was conducted on data from 5098 infants participating in a placebo-controlled trial.
- Infants were categorized based on breastfeeding frequency: never breastfed, sometimes breastfed, and exclusively breastfed.
- Vaccine efficacy against any RVGE severity and severe RVGE was calculated for each breastfeeding group.
Main Results:
- Vaccine efficacy against any RVGE severity was 68.3% (never breastfed), 82.2% (sometimes breastfed), and 68.0% (exclusively breastfed).
- Vaccine efficacy against severe RVGE was 100% (never breastfed), 95.4% (sometimes breastfed), and 100% (exclusively breastfed).
- No adverse impact of breastfeeding frequency on pentavalent rotavirus vaccine efficacy was observed.
Conclusions:
- Breastfeeding frequency does not appear to diminish the protective effect of the pentavalent rotavirus vaccine.
- The pentavalent rotavirus vaccine maintains high efficacy regardless of infant breastfeeding status.
- Findings support the concurrent use of rotavirus vaccination and breastfeeding for optimal infant protection.
Abstract:
The efficacy of a live, oral, pentavalent rotavirus vaccine against G1-4 rotavirus gastroenteritis (RVGE) was retrospectively assessed based on breastfeeding frequency among 5098 infants in a placebo-controlled trial. The efficacy against any RVGE severity for infants never breastfed, sometimes breastfed, or exclusively breastfed was 68.3%, 82.2%, and 68.0%, respectively. The efficacy against severe RVGE was 100%, 95.4%, and 100%, respectively. Breastfeeding did not seem to adversely impact the efficacy of pentavalent rotavirus vaccine.
Related Concept Videos
Respiratory Syncytial Virus Disease
Development of Human Microbiota
Vaccinations
